Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial (07 May 2008) First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra % with Menactra, as measured by the hSBA assay. SerogroupY causes approximately 39... a greater immune response against meningococcal serogroups A, C, W-135 and Y... higher levels of antibodies against all four serogroups. Notably for serogroup...
Top